Perspective Therapeutics (CATX) Income from Non-Controlling Interests (2016 - 2023)
Perspective Therapeutics' (CATX) quarterly Income from Non-Controlling Interests came in at $289000.0 in Q4 2023, up 312.86% year-over-year from $70000.0 in Q4 2022, and up 1826.67% quarter-over-quarter from $15000.0 in Q2 2023.
Powered by 
Analysis
Perspective Therapeutics (CATX) Income from Non-Controlling Interests (2016 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Income from Non-Controlling Interests across 3 years of filings, most recently posting $289000.0 for Q4 2023.
- In Q4 2023, Income from Non-Controlling Interests rose 312.86% year-over-year to $289000.0; the TTM figure through Sep 2024 stood at $289000.0 (up 240.0% YoY), while the FY2023 annual figure was $304000.0, up 334.29% from the prior year.
- Income from Non-Controlling Interests came in at $289000.0 for Q4 2023 at Perspective Therapeutics, up from $15000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $289000.0 in Q4 2023 to a low of $15000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -100.77 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 289,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Dec 31, 2022 | 70,000.00 |
| Dec 31, 2016 | 48,000.00 |
| Jun 30, 2016 | 456,000.00 |